Ajinomoto Co., Ltd.

Other

Yuzuru Eto

Naohiro Miyamura

Reiko Yasuda

Hiroaki Nagasaki

Yusuke Amino

Hiroshiro Shibai

Daisuke Ejima

Shigeru Yamanaka

Sen Takeshita

Satoshi Takano

Takeaki Ohsu

Kenzo Yokozeki

Seiichi Sato

Shunichi Suzuki

Kiyoshi Miwa

Masayuki Sugiki

Toshihiro Hatanaka

Kenichi Hashiguchi

Sayaka Asari

Tetsuo Yano

Katsunori Kobayashi

Toru Okamatsu

Fumie Futaki

Shigekatsu Tsuchiya

Yayoi Kawato

Yoshiro Kitahara

Kunio Ono

Yuko Tanita

Takaho Tajima

Tomohiko Yamanaka

Takashi Miyaki

Yukie Seki

Kunihiko Watanabe

Akira Okano

Keiji Iwasaki

Kazutami Sakamoto

Tsuyoshi Ohsumi

Yoshinobu Takino

Tomohiro Kodera

Takami Maekawa

Naoto Koyama

Katsuya Seguro

Etsuro Ogata

Eiji Shiojiri

Megumi Kaneko

Itaru Kojima

Shigeru Shioya

Yasunori Yokogawa

Yumiko Suzuki

Chiori Ijichi

Yutaka Ishiwatari

Yuko Kai

Tomoko Tsuji

Misako Takezawa

Sachise Eto

Yuki Tahara

Yoshinori Mine

Hideki Taniguchi

Atsushi Suzuki

Hiromi Chujou

Tetsuro Izumi

Junya Yoneda

Michiro Sasaki

Makoto Shiozaki

Yasuo Totsuka

Masayo Washitake

A substance is described which is capable of imparting a kokumi, which shows a more excellent kokumi-imparting effect, in particular, the initial taste-imparting type of kokumi-imparting effect, which is excellent in the stability and which can easily be produced at a low cost. Additionally, a kokumi-imparting composition which includes a substance as well as a kokumi-imparting agent including the substance and other substances possessing the CaSR agonist activities in combination. More particularly, the present invention herein provides a kokumi-imparting composition consisting of &#x3b3;-Glu-Abu (L-&#x3b3;-glutamyl-L-2-amino-butyric acid) and a complex kokumi-imparting agent which includes the foregoing substance and another substance having a CaSR agonist activity, in combination.

Use of peptides for imparting kokumi

The body taste of a sweetener (for example, aspartame, sucralose, acesulfame, etc.) is improved by blending the sweetener with an amino acid or a peptide, which is able to activate a calcium receptor, such as &#x3b3;-Glu-X-Gly (wherein X represents an amino acid or an amino acid derivative), &#x3b3;-Glu-Val-Y (wherein Y represents an amino acid or an amino acid derivative), &#x3b3;-Glu-Ala, &#x3b3;-Glu-Gly, &#x3b3;-Glu-Cys, &#x3b3;-Glu-Met, &#x3b3;-Glu-Thr, &#x3b3;-Glu-Val, &#x3b3;-Glu-Orn, Asp-Gly, Cys-Gly, Cys-Met, Glu-Cys, Gly-Cys, Leu-Asp, D-Cys, &#x3b3;-Glu-Met(O), &#x3b3;-Glu-&#x3b3;-Glu-Val, &#x3b3;-Glu-Val-NH, &#x3b3;-Glu-Val-ol, &#x3b3;-Glu-Ser, &#x3b3;-Glu-Tau, &#x3b3;-Glu-Cys(S-Me)(O), &#x3b3;-Glu-Leu, &#x3b3;-Glu-Ile, &#x3b3;-Glu-t-Leu, &#x3b3;-Glu-Cys(S-Me), etc.

Sweetener

The present invention encompasses a method for screening for a kokumi-imparting substance by using the calcium receptor activity as an index, a composition containing a kokumi-imparting substance obtained by the screening method, a method for producing food or drink imparted with kokumi, and food or drink imparted with kokumi.

Kokumi-imparting agent

By contacting a test substance with a cell that expresses a Kv3.2 protein, and comparing observed cation influx into the cell with cation influx into the cell observed when the test substance is not contacted with the cell, a salty taste modulating substance such as salt alternative compound, or salt perception enhancing or inhibiting compound is screened.

Method for screening a salty taste modulating substance

By searching various kinds of compounds having CaSR agonistic activity, the present invention provides CaSR agonistic agents, pharmaceutical compositions, preventive or therapeutic agents for diarrhea and kokumi-imparting agents each of which comprise the compound. More specifically, the present invention provides CaSR agonistic agents, pharmaceutical compositions, preventive or therapeutic agents for diarrhea and kokumi-imparting agents each of which comprise a glutamic acid derivative having CaSR agonistic activity or pharmaceutically acceptable salts thereof.

CaSR agonists

An object is to provide a CaSR agonist agent that has excellent CaSR agonist effects, and particularly, a pharmaceutical product that can prevent or remedy diabetes or obesity by the effect of CaSR activation. The aforementioned object is achieved by a composition that contains a compound represented by the following General Formula (I) or a salt thereof (refer to the Description for the definitions of the symbols used in the formula). 

Prophylactic or therapeutic agent for diabetes or obesity

A medicament having an excellent CaSR agonist action which enables the prevention or treatment of diabetes or obesity is provided by a composition comprising the compound represented by general formula (I) as defined, or a salt thereof.

Prophylactic agent or therapeutic agent for diabetes or obesity

The present invention provides a variety of compounds having a CaSR agonist activity which possesses a superior kokumi-imparting function, and more particularly provides a kokumi-imparting composition, which contains the foregoing compound, and/or another substance having a CaSR agonist activity, in combination. The present invention also provides a kokumi-imparting composition which includes a lanthionine derivative and/or another substance having a CaSR agonist activity.

Lanthionine derivatives

A substance capable of imparting a kokumi having CaSR agonist activity is described. This substance is able to impart kokumi in a superior manner, in particular, at the initial taste, and is also highly stable and can easily be produced at a low cost. The present invention thus provides a kokumi-imparting composition which includes such a substance as well as a complex kokumi-imparting composition which includes the substance and other substances possessing the CaSR agonist activities in combination. More particularly, the present invention herein provides a kokumi-imparting composition including &#x3b3;-Glu-Nva (L-&#x3b3;-glutamyl-L-norvaline), and a complex kokumi-imparting composition including the foregoing substance and another substance having a CaSR agonist activity, in combination.

An immunostimulating agent, which can stimulate immunity effectively, is described. The immunostimulating agent contains an active ingredient including a calcium receptor activator such as &#x3b3;-Glu-X-Gly [wherein X represents an amino acid or a derivative thereof other than Cys], &#x3b3;-Glu-Val-Y [wherein Y represents an amino acid or a derivative thereof], &#x3b3;-Glu-Ala, &#x3b3;-Glu-Gly, &#x3b3;-Glu-Met, &#x3b3;-Glu-Thr, &#x3b3;-Glu-Val, &#x3b3;-Glu-Orn, Asp-Gly, Cys-Gly, Cys-Met, Glu-Cys, Gly-Cys, Leu-Asp, &#x3b3;-Glu-Met(O), &#x3b3;-Glu-&#x3b3;-Glu-Val, &#x3b3;-Glu-Val-NH2, &#x3b3;-Glu-Val-ol, &#x3b3;-Glu-Ser, &#x3b3;-Glu-Tau, &#x3b3;-Glu-Cys(S-Me)(O), &#x3b3;-Glu-Leu, &#x3b3;-Glu-Ile, &#x3b3;-Glu-t-Leu, &#x3b3;-Glu-Cys(S-Me), a cation having a valency of 2 or more, protamine, polylysine, spermine, spermidine, putrescine, cinacalcet, a cinacalcet analogue compound, and a salt of any one of the aforementioned components.

Immunostimulating agent

Kokumi-imparting agent, method of using, and compositions containing same

A low-fat food containing an amino acid or a peptide which is able to activate a calcium receptor, examples of which include &#x3b3;-Glu-X-Gly, &#x3b3;-Glu-Val-Y, &#x3b3;-Glu-Ala, &#x3b3;-Glu-Gly, &#x3b3;-Glu-Cys, &#x3b3;-Glu-Met, &#x3b3;-Glu-Thr, &#x3b3;-Glu-Val, &#x3b3;-Glu-Orn, Asp-Gly, Cys-Gly, Cys-Met, Glu-Cys, Gly-Cys, Leu-Asp, D-Cys, &#x3b3;-Glu-Met(O), &#x3b3;-Glu-&#x3b3;-Glu-Val, &#x3b3;-Glu-Val-NH, &#x3b3;-Glu-Val-ol, &#x3b3;-Glu-Ser, &#x3b3;-Glu-Tau, &#x3b3;-Glu-Cys(S-Me)(O), &#x3b3;-Glu-Leu, &#x3b3;-Glu-Ile, &#x3b3;-Glu-t-Leu, &#x3b3;-Glu-Cys(S-Me), etc, wherein X and Y are an amino acid or an amino acid derivative.

Food

A calcium receptor activator and compositions containing at least one of the following: &#x3b3;-Glu-Cys-Gly, &#x3b3;-Glu-Cys(SNO)-Gly, &#x3b3;-Glu-Ala, &#x3b3;-Glu-Gly, &#x3b3;-Glu-Cys, &#x3b3;-Glu-Met, &#x3b3;-Glu-Thr, &#x3b3;-Glu-Val, &#x3b3;-Glu-Orn, Asp-Gly, Cys-Gly, Cys-Met, Glu-Cys, Gly-Cys, Leu-Asp, D-Cys, &#x3b3;-Glu-Met(O), &#x3b3;-Glu-Val-Val, &#x3b3;-Glu-Val-Glu, &#x3b3;-Glu-Val-Lys, &#x3b3;-Glu-&#x3b3;-Glu-Val, &#x3b3;-Glu-Val-NH, &#x3b3;-Glu-Val-ol, &#x3b3;-Glu-Ser, &#x3b3;-Glu-Tau, &#x3b3;-Glu-Cys(S-Me)(O), &#x3b3;-Glu-Leu, &#x3b3;-Glu-Ile, &#x3b3;-Glu-t-Leu, &#x3b3;-Glu-Cys(S-allyl)-Gly, &#x3b3;-Glu-Gly-Gly, &#x3b3;-Glu-Val-Phe, &#x3b3;-Glu-Val-Ser, &#x3b3;-Glu-Val-Pro, &#x3b3;-Glu-Val-Arg, &#x3b3;-Glu-Val-Asp, &#x3b3;-Glu-Val-Met, &#x3b3;-Glu-Val-Thr, &#x3b3;-Glu-Val-His, &#x3b3;-Glu-Val-Asn, &#x3b3;-Glu-Val-Gln, &#x3b3;-Glu-Val-Cys, &#x3b3;-Glu-Val-Orn, &#x3b3;-Glu-Ser-Gly, &#x3b3;-Glu-Cys(S-Me), &#x3b3;-Glu-Abu-Gly, &#x3b3;-Glu-Cys(S-Me)-Gly, and &#x3b3;-Glu-Val-Gly.

Calcium receptor activator

Growing community of inventors

Kawasaki, Japan

Yuzuru Eto